## Abstract ## BACKGROUND The efficacy of second‐line chemotherapy for patients with recurrent or progressive oligodendroglial tumors is limited. In the current study, the authors investigated the use of carboplatin as a second‐line chemotherapeutic agent against these types of tumors. ## METHODS
Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors
✍ Scribed by Luciano Scopece; Enrico Franceschi; Giovanna Cavallo; Anna Paioli; Gabriele Paioli; Rosa Conforti; Emanuela Palmerini; Carlotta Berzioli; Federica Spagnolli; Roberta Degli Esposti; Lucio Crinò
- Publisher
- Springer US
- Year
- 2006
- Tongue
- English
- Weight
- 151 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0167-594X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. ## METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurre
## Abstract Ifosfamide, carboplatin, and etoposide (ICE) chemotherapy has promising activity against various solid tumors but produces significant myelotoxicity that might be ameliorated by hematopoietic growth factors. Twelve patients with relapsed solid tumors were treated with ICE chemotherapy.
Background. Carboplatin is an analogue of cisplatin with less nonhematologic toxicity than